10x Genomics ($TXG) Insider Trading & Smart Money Activity
10x Genomics, Inc. ($TXG) has 4 insider trades, 3 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($3.72M), net -$3.72M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$3.72M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 3
- Analyst ratings on file
- 1
TXG insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 2 · $1.22M | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 2 · $2.50M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 1 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All TXG insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13F | Counterpoint Mutual Funds | New | +125.77K sh | $11.36M | — | ||||||
| Insider | Shehnaaz SulimanDirector | Sell (Open-market sale) 10b5-1 | 5.72K sh | $464.67K | +11.6% | — | |||||
| Insider | Saxonov SergeChief Executive Officer | Sell (Open-market sale) 10b5-1 | 25K sh | $2.03M | +11.6% | — | |||||
| Analyst | Barclays | Reiterates to buy | PT $40 | +12.9% | +33.7% | Read | |||||
| Insider | Serge SaxonovChief Executive Officer | Sell (Open-market sale) 10b5-1 | 30K sh | $1.03M | +12.8% | +42.8% | — | ||||
| Insider | Shehnaaz Suliman | Sell (Open-market sale) 10b5-1 | 5.72K sh | $186.76K | +0.4% | +40.1% | — | ||||
| 13F | ARK Investment Management | Reduced | -950.05K sh | $337.93M | +6.5% | +38.9% | — | ||||
| 13F | ARK Investment Management | Reduced | -950.05K sh | $449.24M | +6.5% | +38.9% | Read |
1W / 1M / 6M = how TXG moved from the trade or filing date.
Insider trading in TXG: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Shehnaaz Suliman | Director | 2 | -$651.43K | Sep 22, 2026 | |
| Saxonov Serge | Chief Executive Officer | 1 | -$2.03M | Sep 22, 2026 | |
| Serge Saxonov | Chief Executive Officer | 1 | -$1.03M | Jun 22, 2026 |
Institutions moving TXG (13F)
Analyst ratings on TXG
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Barclays | Reiterates | buy | $40 | +12.9% | +33.7% | Read |
Frequently asked questions
Are TXG insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 4 open-market sales worth $3.72M, a net -$3.72M.
What is the latest insider trade in TXG?
Shehnaaz Suliman, Director filed a sell (open-market sale) of 5.72K sh worth $464.67K on Sep 22, 2026.
Which institutions changed their TXG positions?
Recent 13F filers moving the stock include ARK Investment Management and Counterpoint Mutual Funds.
Other medical devices stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.